Please try another search
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Laurence Hicks | 56 | 2021 | Independent Director |
Punit S. Dhillon | 42 | 2018 | Independent Director |
Guy Lyndon Fish | 62 | 2021 | Independent Director |
Terrence W. Norchi | 57 | 2006 | Co-Founder, Chairman, President & CEO |
Matthew G. Garoufalis | - | 2023 | Member of Medical Advisory Board |
Brock A. Liden | - | 2023 | Member of Medical Advisory Board |
Terry A. Treadwell | - | 2023 | Member of Medical Advisory Board |
Gregory A. Bohn | - | 2023 | Member of Medical Advisory Board |
John C. Lantis | - | 2023 | Member of Medical Advisory Board |
Lawrence A. DiDomenico | - | - | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review